22 results about "Transplant Procedure" patented technology

Decellularized and shaped corneal tissue lenticules from allograft and / or xenograft sources and methods of obtaining such lenticules are disclosed. The lenticules are particularly useful as intrastromal lenticular implants in keratoplasty procedures, in which a hinged flap is formed in a patient's cornea and folded back along its hinge to expose the stromal bed of the cornea. The shaped lenticule is then applied to the stromal bed and the flap returned to its original position yielding a new curvature for the cornea and resulting in a desired refractive correction. Fine-tuning of the new refractive power can be achieved by laser ablation either at the same time as implantation or at later time in the event of regression or tonus changes. Methods of decellularizing cornea tissue are disclosed to reduce potential immunogenic reactions on the part of the patient to the implanted lenticule. The lenticules can be further treated to remove immunogenic epitopes. In addition, the posterior and / or anterior surfaces of the lenticule can be treated to assist in intrastromal seating of the lenticule and / or to reduce the likelihood of dislodgement. The methods of forming lenticules can further include preserving at least a portion of the Bowman's membrane. The smoothness of the Bowman's membrane surface also makes it less likely that reopening the flap will dislodge the lenticule.

Disclosed herein are anti-CD45 antibodies, antigen-binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. The antibodies and ADCs can be used in therapeutic methods including methods of depleting CD45 + cells in a patient. The compositions and methods described herein can be used for direct treatment of conditions, for example, by depleting CD45 + cancer cells or populations of autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplantation therapy and to improve the implantation of hematopoietic stem cell grafts by selectively depleting endogenous CD45 + cells prior to the transplantation procedure.

1. The name of the design product: corneal visible trepan. 2. The use of the design product: the design product is used for drilling cornea in corneal transplantation operation. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

Allogeneic kidney transplantation is a common transplant procedure and an optimal form of therapy for individuals who reach end-stage renal disease, significantly improving their quality of life, as compared to dialysis and supportive care. Nonetheless, its success relies on lifelong immunosuppression (IS), which causes serious complications. Moreover, despite immunosuppression (IS), around 8% of renal transplants will be rejected due to T cell-mediated and / or antibody-mediated reactions towards donor-specific allo-antigens. Importantly, scarce kidney recipients achieve an immunosuppressive drug-free tolerance, suggesting the existence of active tolerance mechanisms. Biomarkers to predict rejection risks and identify patients in which tolerance mechanisms could allow IS weaning, as well as a non-invasive biomarker to diagnose a rejection event, are highly needed to improve patient's care. The inventors identify circulating CD73+ DP8α Tregs or the expansion of CD73+ DP8α Tregs after transplantation as a non-invasive biomarker to predict rejection risks from 3 months post-transplantation. These data advocate for the potential value of these cells to improve kidney grafted patients' care through IS minimization and / or tolerance-inducing therapies. Strikingly, these results were observed in two independent cohorts, at 1-year post-transplantation. The present invention relates to a method of determining in a subject whether a subject has or is at a risk of developing transplant rejection comprising the steps of: i) determining the frequency of CD73-expressing DP8α Tregs among any T cell subset in particular among total CD3+ T cells or among total CD4+ T cells or among total CD8+ T cells in a sample obtained from the subject after transplantation, ii) comparing the frequencies determined at step i) with a predetermined reference value wherein detecting differential between the frequency of CD73- expressing DP8α Tregs among any T cell subset in particular among total CD3+ T cells or among total CD4+ T cells or among total CD8+ T cells determined at step i) and the predetermined reference value is indicative of whether a subject has or is at a risk of developing a transplant rejection.

The invention relates to a construction method of tissue engineering corneal epithelial cells. The construction method comprises the following steps: obtaining corneal limbus tissue blocks; digesting the tissue block, and separating to obtain epithelial cells of the tissue block; the method comprises the following steps: attaching epithelial cells to ultrathin amniotic membrane-umbilical cord derived mesenchymal stem cells, culturing in an SHEM culture medium, changing the SHEM culture medium once every two days, culturing for a period of time, and culturing the epithelial cells for a period of time by using a gas-liquid interface culture method to promote the multi-layer growth of the epithelial cells, thereby obtaining the tissue engineering corneal epithelial cells. Through a controllable preparation scheme, the amniotic membrane carrier with a certain thickness is obtained so as to increase the transparency of the amniotic membrane carrier, meanwhile, the matrix surface of the amniotic membrane carrier is inoculated with MSC, the healthy corneal limbus matrix microenvironment of a human body is simulated, damaged corneal limbus tissue / corneal epithelium is better repaired or regenerated, and the ocular surface microenvironment is improved. The produced ultrathin amnion combined mesenchymal stem cell carrier can obviously improve the effect of a tissue engineering corneal epithelium transplantation operation.

A powder formulation for preserving tissue and organ function, and more particularly to shelf stable powder formulations that can be reconstituted at point of use, including during a fat grafting process, coronary artery bypass graft surgery, and peripheral bypass surgery, or other grafting / transplant surgery prior to or during the medical procedure to preserve the tissues / organs used in these procedures. The powder formulation includes a reducing agent; an antioxidant; a sugar; a nitric oxide substrate; a buffering agent; and physically acceptable salt. Also provided are a method of preparing an organ or tissue preservation solution by reconstituting the powder formulation, and a method of preserving tissue or an organ using same.

There is disclosed a defect sizer tool for selection of an appropriately sized pre-cut core for a cryopreserved osteochondral allograft (COCA) transplantation procedure. In an embodiment, the tool includes an elongated connector that provides a handle portion. A ring measurement guide at one end, with a given diameter, and alignable with a cartilage defect to provide an estimated measurement of a diameter. There is disclosed an instrument kit with a pin, a pin guide, and a reamer configured to slidingly receive the pin, blades at one end, and a rotational drive connector at the other end. In an embodiment, a method for a COCA transplantation procedure includes providing an instrument kit, using the pin guide to place the pin in the subchondral bone, and operating the reamer to score surrounding cartilage prior to the reamer bit portion reaming the subchondral bone to the desired depth. Other embodiments are also disclosed.

Provided herein are methods and systems of transplant cells and growing an ectopic tissue in a lymph node of a subject. In certain embodiments, the methods and systems provided herein enable minimally invasive cell transplantation to treat patients in need thereof. In certain embodiments, the methods and systems provided herein include the use of ultrasound endoscopy.

The invention provides an organ perfusion preserving fluid based on mesenchymal stem cell extracellular vesicles, a preparation method and application of the extracellular vesicles in preparation of the organ perfusion preserving fluid. The organ perfusion preserving fluid is used for perfusion in in-vitro preservation and transplantation operations, the organ perfusion preserving fluid comprises umbilical cord mesenchymal stem cell extracellular vesicles subjected to extraction, purification and freeze-drying treatment, and the treated extracellular vesicles contain bioactive components including protein, lipid, mRNA and miRNA. The organ perfusion preserving fluid further comprises basic HTK liquid, standard HTK liquid components and auxiliary materials. The organ perfusion preserving fluid provides wider protection at the cellular level through various bioactive components such as protein, lipid, mRNA and miRNA in extracellular vesicles, and reduces oxidative stress and metabolic damage during in-vitro preservation.

The embodiment of the application discloses a kind of fecal bacteria transplantation donor-recipient dynamic matching method, device, equipment and medium, in response to donor-recipient matching request, the fecal bacteria transplantation after monitoring data of current preset sampling time of to-be-matched recipient is acquired;Wherein, the fecal bacteria transplantation after monitoring data is determined based on the fecal bacteria group of any one target donor to to-be-matched recipient after completing fecal bacteria transplantation operation, and the target donor is determined based on the genetic feature information, immune feature information and clinical feature information of to-be-matched recipient and multiple candidate donors for adaptability matching;Fecal bacteria transplantation after monitoring data is input into transplantation strategy control model, and at least one of the donor switching strategy and dose adjustment strategy for adjusting to-be-matched recipient in next period is output, overall compatibility evaluation is realized by multi-modal data integration, and treatment scheme is continuously optimized by means of dynamic feedback mechanism, which significantly improves the precision and adaptability of fecal bacteria transplantation treatment.

Amatoxins, as well as antibody-drug conjugates (ADCs) and compositions have amatoxin and can be used for cancer therapy, to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions treat various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases and prevent graft-versus-host disease (GVHD).

A method for detecting biometric parameters includes the steps of performing a bone graft procedure on at least one vertebra of a spine, providing at least one biometric sensor at the at least one vertebra, the sensor measuring at least one parameter selected from the group consisting of pressure, tension, shear, relative position, and vascular flow in an adjacent surrounding, and measuring the at least one biometric parameter at the vertebra with the sensor.

The utility model discloses a blood vessel cannula for rat liver transplantation, which comprises a cylindrical cannula body, a through hole is arranged on the cannula body, one end of the cannula body is fixedly connected with a clamping handle, an annular binding groove is arranged on the outer wall of the cannula body, and the binding groove is positioned on one side far away from the clamping handle. According to the utility model, when a liver transplantation operation is carried out on a rat, an operator can use tweezers to clamp the clamping handle, clamp up the sleeve, then sleeve the tube body on one blood vessel and enable the blood vessel to pass through the through hole, and then turn one end of the blood vessel outwards and sleeve the outer wall of the tube body; finally, the other blood vessel is connected with the clamping handle in a sleeved mode and is bundled and fixed, the transplantation operation can be completed, in the operation process, tweezers clamp the clamping handle, the tube body can be made to be stable, the blood vessel can penetrate through the tube body more rapidly, and therefore the operation time is shortened, and the operation efficiency is improved.

Amatoxins, as well as antibody-drug conjugates (ADCs) comprising an amatoxin are provided, as well as compositions and methods of using the same. The compositions and methods provided herein can be used for cancer therapy. They can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure. Methods and compositions for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, as well as prevention of graft-versus-host-disease (GVHD), are provided.

The invention concerns a method, and a device that can implement this method, adapted to obtain adipose based compounds, of selectively variable particle sizes, distinguished by high levels of purity and by high concentrations of viable mesenchymal stem cells, which can be used in autologous transplantation procedures mainly for regenerative purposes, as well as for filling and / or volumizing purposes.

The present disclosure provides a solution for maintaining, by monitoring and guidance operations, a desired condition state in an eye of the subject, following an ophthalmological procedure. For example, the procedure may be corneal transplant, either a complete transplant of a corneal or a partial transplant of some layers of the cornea. Following the procedure, a gas bubble is injected into the eye to maintain the corneal graft in position. As long as the gas bubble is located below the corneal graft, it assists in maintaining the graft in position. As the gas bubble is lighter than the medium in the eye, it keeps pushing upwards and applying forces on the graft and preventing it from dislocating. The present disclosure provides a solution that keeps monitoring the gas bubble, or any other condition state resulted by an ophthalmological procedure and providing instructions to the subject in case the gas bubble deviates from certain allowed boundaries within the eye.

The application discloses a single device of a chain-pot seedling transplanting machine matched with a conventional regular hexagonal cross-section paper chain-pot seedling book technology, and realizes automatic seedling supplying, seedling transporting, chain-pot breaking, seedling pushing and transporting, ditching, soil covering and pressing and other transplanting procedures through mechanical structures such as a seedling receiving device, a profiling device, a chain-pot breaking device, a double-finger holding and seedling pushing device and a soil covering and pressing device. The application realizes chain-pot breaking, high speed and automatic transplanting of large-plant-distance crop chain-pot seedling books by using a pure mechanical structure, and can effectively solve the problems of high labor intensity and low operation efficiency of manual transplanting and semi-automatic mechanical transplanting in China, and lays a foundation for the development of transplanting technology in the direction of labor saving and unmanned.

Tools and methods for use in arthroscopic bone grafting procedures, for example. A bone grafting tool can include a cannulated shaft having a first and second sections, where the first and second section may define a flow path between a first end and a second end of the shaft. The bone grafting tool can include a shaped head coupled to the second section at the second end of the shaft. The head can include an aperture in flow communication with the second section, where the aperture may be positioned at or near normal to an axis of the second section. The second section can be coupled to the first section at an angle, and the first end of the shaft can include means for attachment to a syringe containing bone grafting material to be used in the disclosed methods.

A paired magnetic retention system for retaining a denture in the mouth for providing synthetic teeth to a dental patient temporarily during a period of healing following bone graft surgery or for a longer period of time for retaining a removable denture in the mouth of a dental patient for providing synthetic teeth to a dental patient for an indefinite length of time. The magnetic retention system comprising a pair of magnetic bodies, one implanted in a bone in the mound that does not regularly support real teeth, and is not generally affected by the usual dental problems causing the loss of a patient's real teeth, and the second magnetic is secured to a part of the denture which comes into contact with the bone in which the first magnetic body is implanted.

This invention provides compositions and methods useful for treating CD45+ cell depletion, and in particular for treating various hematopoietic disorders, metabolic disorders, cancer, and autoimmune diseases. [Solution] The compositions and methods described herein can be used, for example, to treat a disorder by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for allogeneic hematopoietic stem cell transplantation therapy and to improve the engraftment of allogeneic hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells before the transplantation procedure.

Disclosed are anti-CD45 antibodies, antigen binding fragments thereof, and antibody drug conjugates (ADCs) that specifically bind to human CD45. Such antibodies and ADCs are useful in therapeutic methods, including methods of depleting CD45+ cells from a patient. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy, and to improve the engraftment of hematopoietic stem cell transplants, by selectively depleting endogenous CD45+ cells prior to the transplant procedure.